Pharma & Biotech Mergers & Acquisitions News
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co 23 October 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure’s key product Optune Lua for lung cancer patients. Also, German biotech BioNTech and its US partner OncoC4 received a partial clinical hold from the FDA on the Phase III trial of gotistobart in lung cancer. The European Medicines Agency’s human health committee, CHMP, Reaffirmed its non-approval of PTC Therapeutic’s Translarna. 20 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Biotechnology
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Pharmaceutical
Germany-headquartered Qiagen has entered into an agreement to acquire STAT-Dx, a privately-held Spanish company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven Qiagen chemistries. 1 February 2018
Biotechnology
USA-based Seattle Genetics is to acquire Cascadian Therapeutics for around $614 million, it was announced on Wednesday. 31 January 2018
Pharmaceutical
Three corporate behemoths have hatched a plan to step in to the American healthcare market, with the aim of “improving employee satisfaction and reducing costs.” 31 January 2018
Biotechnology
French pharma major Sanofi revealed that it has entered into a definite agreement to acquire Belgium biotech firm Ablynx. 29 January 2018
Pharmaceutical
Last week’s impact news started with the announcement of two major acquisition deals: Sanofi’s $11.6 billion deal with Bioverativ, which has been widely slammed as the French pharma paying too much, and Celgene revealing an agreed, previously rumored, $9 billion takeover of CAR-T cell therapy specialist Juno Therapeutics. Added to this, there was BioCryst’s merger with Idera. Additionally, Puma Biotechnology announced that it expected a “negative trend vote” from the European Medicines Agency’s advisory committee on its breast cancer drug Nerlynx at next month’s meeting, while Swiss pharma giant Novartis revealed that it is paying Spark Therapeutics $105 million for European rights to gene therapy eye drug Luxturna. 28 January 2018
Biotechnology
BioCryst Pharmaceuticals and Idera Pharmaceuticals have announced that they have signed a definitive merger agreement to form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases. 23 January 2018
Biotechnology
Shares in neurological diseases specialist Acorda Therapeutics closed up nearly 9% on Friday following reports that a host of companies are interesting in taking over the US biotech. 22 January 2018
Biotechnology
Following last week’s speculation that a takeover bid was on the way for US CAR-T cell therapy specialist Juno Therapeutics, which sent the firm’s shares rocketing 50%, the bid has now been formally announced. 22 January 2018
Pharmaceutical
France’s largest drugmaker Sanofi revealed this morning that it has entered into a definitive agreement to acquire all of the outstanding shares of Bioverativ for $105 per share in cash, which represents a substantial 64% premium to Bioverativ's closing price on January 19, 2018. 22 January 2018
Pharmaceutical
Regulatory decisions from the US Food and Drug Administration featured in the news last with, with a negative advisory panel vote on Aradigm’s antibiotic candidate Linhaliq and news of acceptance of a Biologicals License Application for a Humira (adalimumab) by Novartis subsidiary Sandoz. On the research front, Eiger Pharmaceutical’s pulmonary arterial hypertension drug ubenimex failed. There was strong speculation that Celgene was planning a takeover bid for CAR-T cell therapy specialist Juno Pharma. Also there was disappointment for Johnson & Johnson with the revocation of Johnson & Johnson’s Zytiga patent. 21 January 2018
Generics
Bangladesh's largest drugmaker Beximco Pharmaceuticals says it has now confirmed its previously-announced acquisition of Nuvista Pharma, a leading pharma company in Bangladesh specializing in hormones and steroid drugs. 19 January 2018
Biotechnology
Danish diabetes care giant Novo Nordisk's decision to go public on January 8 after the board of Belgian biotech firm Ablynx flatly rejected its two acquisition offers is misguided, noted analysts at Jeffries in a note issued today. 17 January 2018
Biotechnology
US biotech major Celgene is reportedly looking at what could be its second big acquisition for 2018, and is said to be discussions to purchase US CAR-T cell therapy company Juno Therapeutics. 17 January 2018
Biotechnology
Belgium’s TiGenix has released positive 52-week data from the Phase III ADMIRE-CD trial investigating Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease. 15 January 2018
Pharmaceutical
After a quiet year of M&A activity in 2017, 2018 has already kicked off with two deals exceeding a billion dollars. Novo Nordisk’s rejected $3.1 billion bid for Belgium’s Ablynx – along with its lead candidate caplacizumab -attracted attention, and expectations of a higher offer, as did Celgene’s proposed $1.1 billion acquisition of Impact Biomedicines and its fedratinib. Among deal-making news, there was Chinese biotech firm BeiGene’s interesting accord with Mirati Therapeutics for lung cancer candidate sitravatinib. Also, AstraZeneca’s US Food and Drug Administration approval of its Lynparza, making it the first drug to be cleared for BRAC-positive breast cancer, has resulted in speculation about competitors. 14 January 2018
Generics
Indian drugmakers Aurobindo, Zydus Cadila, Torrent Pharmaceuticals and Intas Pharmaceuticals are among suitors vying for Sanofi’s (Euronext: SAN) attention, as the French drugmaker looks to offload its European generics business. 12 January 2018
Pharmaceutical
Pre-clinical and clinical lab services provider Charles River Laboratories International has acquired KWS BioTest, a contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. 11 January 2018
Biotechnology
Following this morning’s confirmation that it had made that Novo Nordisk has made an increase, unsolicited bid to acquire Belgian biotech firm Ablynx, the latter responded in the afternoon saying the offer fundamentally under-values the company. 8 January 2018
Biotechnology
US biotech Celgene became the first drugmaker of 2018 to announce an acquisition worth more than $1 billion on Sunday with news that it is to buy Impact Biomedicines. 8 January 2018
Pharmaceutical
Takeda Pharmaceutical has announced its intention to launch a voluntary conditional takeover bid for Belgium-based biopharma company TiGenix. 5 January 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze